Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).
作者： Joshua Bauml , Tanguy Y. Seiwert , David G. Pfister , Francis P. Worden , Stephen V. Liu
DOI: 10.1200/JCO.2016.34.15_SUPPL.6011
关键词: Treatment options 、 Medicine 、 Internal medicine 、 Pembrolizumab 、 Head and neck squamous-cell carcinoma 、 Oncology 、 Cetuximab
摘要: 6011Background: Current treatment options for patients (pts) with recurrent/metastatic (R/M) HNSCC who progress on platinum and cetuximab have very limited efficacy. Pembrolizumab, an anti–PD-1 ant...
sci-hub.st 参考文章(0)